Ascendia Pharmaceutical Solutions will participate in the upcoming CRBE Summit West, a technical forum focused on controlled release, bioavailability enhancement, and continuous manufacturing. The event brings together formulation scientists, development leaders, and manufacturing decision makers working on complex drug delivery challenges.
Ascendia Pharmaceutical Solutions specializes in formulation development and manufacturing strategies for poorly soluble and complex drug product candidates Unlike conventional drug delivery companies that require technology access fees and royalties, Ascendia is a CDMO that operates on a straightforward fee-for-service business model.
However, clients still have access to Ascendia’s proprietary nanotechnology platforms that include nano/micro-emulsions, solid nanoparticles, lipid nanoparticles, and amorphous solid dispersions. These core technologies and other capabilities address needs for bioavailability enhancement, drug product stability improvement, as well as modified and controlled release dosage forms (including long-acting injectables). Ascendia’s integrated development approaches are designed to further support clinical and commercial supply via the company’s GMP aseptic and non-aseptic manufacturing and analytical services. Moreover, Ascendia’s capabilities align directly with the scientific themes addressed at the CRBE Summit West.
Dr. Shaukat Ali, Ph.D., will deliver a technical presentation titled “Formulation Technologies for Tackling Solubility and Bioavailability Challenges.” The session is scheduled for Wednesday, February 25th, at 3 PM Pacific Time in the Fairway Ballroom at the Hilton La Jolla Torrey Pines. The presentation will examine formulation technologies used to address solubility-limited compounds and improve oral bioavailability, reflecting Ascendia Pharmaceutical Solutions’ development-driven approach to complex molecules.
Throughout the conference, Ascendia Pharmaceutical Solutions will be available for targeted discussions on formulation development, scale-up, and manufacturing strategies. Bob Bloder, Chief Business Officer, and Dr. Shaukat Ali, Ph.D., will host one-on-one meetings at Ascendia’s table in the Fairway Ballroom exhibition are to discuss specific development challenges, program timelines, and technical requirements.
CRBE Summit West provides a focused setting for in-depth technical conversations. Companies seeking formulation solutions for solubility, bioavailability, or controlled release programs are encouraged to schedule meetings in advance with Ascendia Pharmaceutical Solutions. Early scheduling ensures dedicated time with senior leadership and technical experts. Contact Ascendia Pharmaceutical Solutions now to arrange a meeting with Bob Bloder or Shaukat Ali, Ph.D., and discuss how advanced formulation technologies can support current and future development programs.
For additional information, please contact Jared Hahn (Sr. Director, Business Development) at jhahn@AscendiaCDMO.com.